FDAmanufacturing / CMC66% confidence
Developing and Manufacturing Drugs Including Biologics
Source: FDA
Why This Matters
Why this matters: provides agency context on manufacturing / CMC that may shape timing or evidence expectations for Janssen; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
This material is intended to be a helpful resource that consolidates information relevant for drug manufacturers making products for the U.S. It is not a comprehensive list of all applicable statutory and regulatory requirements.
Supporting Context
- Therapeutic area
- Oncology · T-cell engagers
- Sub-indication
- General
Related signal: FDA Accepts Supplemental BLA for TALVEY (TALQUETAMAB-TGVS) by Janssen